Progress in the application of cytokines in lung cancer treatment
DOI:
https://doi.org/10.54097/zq3ga069Keywords:
Lung cancer; treatment; immunotherapy; cytokine.Abstract
Lung cancer is the most common cancer today and has become the leading cause of cancer death worldwide. Previous common therapy of this disease mainly include surgery, radiation therapy, chemotherapy etc., and the recently most focused solution of immunotherapy, therapy making use of immunity agents such as vaccines, monoclonal antibodies and cytokines. Cytokines, such as gefitinib, the epidermal growth factor receptor inhibitor, and bevacizumab, the VEGF inhibitor, have been widely used in the clinic as targets for the treatment of lung cancer. Another application of cytokines in the treatment of lung cancer is to play the role of biomarkers to provide an important judgment basis for prognosis and diagnosis. However, based on understanding of the advantages and limitations of cytokine therapy, scientists have ceased to make efforts to develop it into a core of the cancer therapy. cytokine’s potential to be combined with other therapies and to play indicative roles in cancer treatment still arouses scientists’ interest. This passage reviews the common treatments of lung cancer and discusses the progress in the application of cytokines as a component of cancer treatment.
Downloads
References
Professional, Cleveland Clinic Medical. “Cytokines.” Cleveland Clinic, my.clevelandclinic.org/health/body/24585-cytokines.
Lee S, Margolin K. Cytokines in Cancer Immunotherapy. Cancers. 2011; 3(4):3856-3893.
Conlon, Kevin C et al. “Cytokines in the Treatment of Cancer.” Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research vol. 39,1 (2019): 6-21.
Ren, Junming et al. “Interleukin-2 superkines by computational design.” Proceedings of the National Academy of Sciences of the United States of America vol. 119,12 (2022): e2117401119.
Ramachandran, Sowmya, et al. “Role of Cytokines and Chemokines in NSCLC Immune Navigatio and Proliferation.” Oxidative Medicine and Cellular Longevity, edited by Jayeeta Ghose, vol. 2021, Hindawi Limited, July 2021, pp. 1–20.
The Cancer Atlas, “Lung Cancer.”, canceratlas.cancer.org/the-burden/lung-cancer.
Travis, William, “Pathology of Lung Cancer”, Clinics in Chest Medicine, vol.32, issue 4, SAUNDERS, Dec.2021, pp. 669-692,
Yale Medicine, “Non-Small Cell Lung Cancer.”, 2022, www.yalemedicine.org/conditions/non-small-cell-lung-cancer.
Professional, Cleveland Clinic Medical. “Lung Cancer.” Cleveland Clinic, my.clevelandclinic.org/health/diseases/4375-lung-cancer.
Miller MC, Mayo KH. Chemokines from a Structural Perspective. International Journal of Molecular Sciences. 2017; 18(10):2088.
Lazear, Helen M et al. “Shared and Distinct Functions of Type I and Type III Interferons.” Immunity vol. 50,4 (2019): 907-923.
Alspach, Elise et al. “Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity.” Cold Spring Harbor perspectives in biology vol. 11,3 a028480. 1 Mar. 2019
Propper, David J, and Frances R Balkwill. “Harnessing cytokines and chemokines for cancer therapy.” Nature reviews. Clinical oncology vol. 19,4 (2022): 237-253.
CUSABIO, “The Overview of Interleukin.”, www.cusabio.com/c-20630.html.
Wang, Xia, and Yong Lin. “Tumor necrosis factor and cancer, buddies or foes?.” Acta pharmacologica Sinica vol. 29,11 (2008): 1275-88.
American Lung association, Lung Cancer Surgery. www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/treatment/types-of-treatment/lung-cancer-surgery.
Hirsch, Fred R., et al. “Lung Cancer: Current Therapies and New Targeted Treatments.” The Lancet, vol. 389, no. 10066, Elsevier BV, Jan. 2017, pp. 299–311.
National Cancer Institute, “Radiation Therapy for Cancer.”, 8 Jan. 2019, www.cancer.gov/about-cancer/treatment/types/radiation-therapy#HRTWAC.
National Cancer Institute, Chemotherapy to Treat Cancer.”, 23 Aug. 2022,www.cancer.gov/about-cancer/treatment/types/chemotherapy.
National Cancer Institute, “Targeted Therapy for Cancer.”, 31 May 2022, www.cancer.gov/about-cancer/treatment/types/targeted-therapies.
Mayekar, Manasi K., and Trever G. Bivona. “Current Landscape of Targeted Therapy in Lung Cancer.” Clinical Pharmacology & Therapeutics, vol. 102, no. 5, Wiley, Sept. 2017, pp. 757–64.
Ventola, C Lee. “Cancer Immunotherapy, Part 1: Current Strategies and Agents.” P & T : a peer-reviewed journal for formulary management vol. 42,6 (2017): 375-383.
Lemjabbar-Alaoui, Hassan et al. “Lung cancer: Biology and treatment options.” Biochimica et biophysica acta vol. 1856,2 (2015): 189-210.
Liu, Chengming, et al. “Systematic Analysis of IL-6 as a Predictive Biomarker and Desensitizer of Immunotherapy Responses in Patients With Non-small Cell Lung Cancer.” BMC Medicine, vol. 20, no. 1, Springer Science and Business Media LLC, May 2022.
Zhang, Jun, and Nirmal Veeramachaneni. “Targeting interleukin-1β and inflammation in lung cancer.” Biomarker research vol. 10,1 5. 27 Jan. 2022
Yan, Xi et al. “Prognosis value of IL-6, IL-8, and IL-1β in serum of patients with lung cancer: A fresh look at interleukins as a biomarker.” Heliyon vol. 8,8 e09953. 13 Jul. 2022
Hardy-Werbin, Max, et al. “Serum Cytokine Levels as Predictive Biomarkers of Benefit From Ipilimumab in Small Cell Lung Cancer.” OncoImmunology, vol. 8, no. 6, Informa UK Limited, Mar. 2019, p. e1593810.
Liu, Yu-Ning, et al. “Macrophage Inhibitory Cytokine-1 as a Novel Diagnostic and Prognostic Biomarker in Stage I and II Nonsmall Cell Lung Cancer.” Chinese Medical Journal, vol. 129, no. 17, Ovid Technologies (Wolters Kluwer Health), Sept. 2016, pp. 2026–32.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







